Results 11 to 20 of about 8,106 (209)

Ticlopidine Alone Versus Ticlopidine Plus Aspirin for Preventing Recurrent Stroke

Internal Medicine, 2003
To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan.A randomized comparative study was performed from April 1992 until December 1995, with follow-up for an average of 1.59 years ...
Mitsuyoshi Nakajima, Akira Takahashi, Eiichi Ito, Shigeki Kuzuhara, Shinichiro Uchiyama, Hiroko Yamamoto   +5 more
openaire   +5 more sources

Ticlopidine-Induced Cholestatic Inflammatory Hepatitis: New Insights into Pathogenetic Mechanisms of Drug-Related Hepatotoxicity [PDF]

European Journal of Inflammation, 2006
In immune-induced liver damage the reactive metabolites may covalently bind or alter liver proteins such as cytochrome P450 enzymes, which leads to activation of the immune system. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome.
I. Kraslova, L. Muchova, L. Vitek, A. Novotny, T. Svestka, R. Bruha   +5 more
doaj   +2 more sources

Interstitial Pneumonia Induced by Ticlopidine.

Circulation Journal, 2002
A 67-year-old female non-smoker, who had been diagnosed with familial hypercholesterolemia associated with severe atherosclerosis of the coronary, carotid and vertebral arteries, developed interstitial pneumonia 4 months after initiating ticlopidine to inhibit platelet aggregation.
Takeshi Matsuo, Toshiro Nagoshi, Tetsunori Ishikawa, Masakazu Maeno, Kazuya Mishima, Ryosai Nakamura, Yoshitake Fujiura, Takuroh Imamura, Hisamitsu Onitsuka, Tanenao Eto, Haruhiko Date, Yasushi Koiwaya   +11 more
openaire   +5 more sources

A Thrombocytopenic Thrombotic Purpura in a Patient With a Metastatic HER2+ Breast Cancer: Description of a Case Report. [PDF]

Clin Case Rep
ABSTRACT Paraneoplastic (p) TTP is a rare syndrome characterized by an immune‐induced, generalized microangiopathy associated with solid or hematological tumors. This case, reporting a patient with a metastatic HER2+ breast cancer and a pTTP, highlights the rarity of this entity, its difficult and challenging diagnosis, and the complexity of its ...
Longo R, Savenkoff B, Ribal R, Dadoun A, Campitiello M, Plastino F, Legros PO, Marcon N, Coppo P, Egea J.   +9 more
europepmc   +2 more sources

French-Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten. [PDF]

Clin Pharmacol Ther
Mavacamten, the first drug in the class of β‐cardiac myosin modulator, is used for the treatment of patients with hypertrophic cardiomyopathy. This orally administered drug demonstrates wide interpatient variability in pharmacokinetics parameters, due in part to variant CYP2C19 alleles.
Lebreton L, Boyer JC, Lafay-Chebassier C, Hennart B, Baklouti S, Cunat S, Vilquin P, Medard Y, Gautier-Veyret E, Laffitte-Redondo C, Verstuyft C, Ait Tayeb AEK, Haufroid V, Wils J, Lamoureux F, Evrard A, Davaze-Schneider J, Ben-Sassi M, Picard N, Quaranta S, Ayme-Dietrich E, French‐Speaking Network of Pharmacogenetics (RNPGx).   +21 more
europepmc   +2 more sources

APLASTIC ANAEMIA AND TICLOPIDINE [PDF]

British Journal of Haematology, 1993
Fernando Sanchez-Gil, Rafael Ramos Fdez-Soria, Eduardo Benitez-cano, Guillermo Martin-Nune   +3 more
openaire   +3 more sources

Genetics of drug‐induced liver injury: Current knowledge and future prospects

Clinical and Translational Science, Volume 16, Issue 1, Page 37-42, January 2023., 2023
Abstract Idiosyncratic drug‐induced liver injury (DILI) remains an important clinical problem, both during drug development and the prescription of a range of licensed drugs. Although rare, the consequences are serious. Ongoing studies on genetic risk factors for DILI, especially genomewide association studies, have resulted in the identification of a ...
Ann K. Daly
wiley   +1 more source

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

European Journal of Clinical Investigation, Volume 53, Issue 1, January 2023., 2023
Abstract Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases.
Quirino Lai, Nicoletta De Matthaeis, Michele Finotti, Giovanni Galati, Giuseppe Marrone, Fabio Melandro, Filomena Morisco, Daniele Nicolini, Riccardo Pravisani, Edoardo G. Giannini, the Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group, Aglitti A, Aliberti C, Baccarani U, Bhoori S, Borzio M, Brancaccio G, Burra P, Cabibbo G, Casadei Gardini A, Carrai P, Cillo U, Conti F, Cucchetti A, D’Ambrosio R, Dell’Unto C, Di Costanzo GG, Di Sandro S, Foschi FG, Fucilli F, Gambato M, Gasbarrini A, Giuliante F, Ghinolfi D, Grieco A, Gruttaduria S, Guarino M, Kostandini A, Iavarone M, Lenci I, Levi Sandri GB, Losito F, Lupo LG, Manzia TM, Mazzocato S, Mescoli C, Miele L, Muley M, Persico M, Plaz Torres MC, Pompili M, Ponziani FR, Rapaccini GL, Rendina M, Renzulli M, Rossi M, Rreka E, Russo FP, Sacco R, Sangiovanni A, Sessa A, Simonetti N, Sposito C, Tortora R, Trevisani F, Viganò L, Viganò M, Villa E, Vincenzi V, Violi P, Vitale A   +70 more
wiley   +1 more source

Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial. [PDF]

Clin Cardiol
DAPT‐MVD is the largest multicenter, parallel, open‐label, randomized controlled study focused on optimal antiplatelet therapy for MVD patients who have undergone DES implantation. The primary objective is to evaluate the efficacy and safety of prolonged DAPT with clopidogrel plus aspirin in these patients 12 months after DES implantation.
Tian J, Wang Z, Wang Y, Wang F, Wang Y, Zhao P, Hou X, Peng X, Tian M, Wang D, Yu B.   +10 more
europepmc   +2 more sources

Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1

Mediators of Inflammation, 2014
Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), like other ectonucleotidases, controls extracellular nucleotide levels and consequently their (patho)physiological responses such as in thrombosis, inflammation, and cancer.
Joanna Lecka, Michel Fausther, Beat Künzli, Jean Sévigny   +3 more
doaj   +1 more source